Anthony Chan

Anthony Chan

Auto-generated profile, based on publicly available information

Anthony Chan

Regional Hepato-Pancreato-Biliary Unit, Manchester Royal Infirmary, Manchester, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
BLBen Lawrence
Ben Lawrence
BGBjorn I. Gustafsson
Bjorn I. Gustafsson
ACAnthony Chan
Anthony Chan
BSBernhard Svejda
Bernhard Svejda
MKMark Kidd
Mark Kidd
IMIrvin M. Modlin
Irvin M. Modlin

3 November 2008 in Cancer
Verified
Journal Article
Open access
PDF file
OHOyvind Hauso
Oyvind Hauso
BGBjorn I. Gustafsson
Bjorn I. Gustafsson
MKMark Kidd
Mark Kidd
Helge WaldumHelge Waldum
Helge Waldum
IDIgnat Drozdov
Ignat Drozdov
IMIrvin Modlin
Irvin Modlin
BACKGROUND.: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program has proven to be a significant resource in US neuroendocrine tumor (NET) epidemiology. Norway also holds a robust and detailed cancer registry: the Norwegian Registry of Cancer (NRC).METHODS.: SEER NET data were compared with corresponding NRC data in the time period 1993 to 2004 to determine whether there are differences in NET epidemiology between Norway and the United States.RESULTS.: The SEER and NRC reported 17,312 and 2030 NETs, respectively. The overall Caucasian SEER NET incidence was 4.44, compared with 3.24 in the NRC. In the SEER white subset, bronchopulmonary NETs were the most common (incidence = 1.42; 32% of all NETs), compared with small intestinal NETs in the NRC (0.81; 26%). A marked increase in SEER NET incidence (37%‐40%) was observed in the period 2000 to 2004, compared with 1993 to 1997; an even more pronounced increase (72%) was seen in the NRC. African Americans exhibited a remarkably high overall NET incidence of 6.50; furthermore, among African Americans, rectal NETs were most common (1.65; 27%). Small intestinal NET incidence was ∼30% higher in men compared with women in all populations. The highest 5‐year survival rates were for rectal NETs (74%‐88%) in both databases, whereas prostatic NETs had the worst outcome (0%‐23%). At diagnosis, NETs were localized in 27% to 46% of patients.CONCLUSIONS.: NET incidence in the US Caucasian population and in Norway is similar, but considerably higher (∼50%) among African Americans. NETs have been regarded as indolent tumors; however, the 5‐year survival is only ∼55%. Cancer 2008. © 2008 American Cancer Society.

20 June 2008 in Cancer
Verified
Journal Article
Closed access
PDF file
BGBjorn I. Gustafsson
Bjorn I. Gustafsson
MKMark Kidd
Mark Kidd
ACAnthony Chan
Anthony Chan
MMMax V. Malfertheiner
Max V. Malfertheiner
IMIrvin Modlin
Irvin Modlin

1 July 2007 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
IMIrvin M. Modlin
Irvin M. Modlin
MCManish C. Champaneria
Manish C. Champaneria
ACAnthony K.C. Chan
Anthony K.C. Chan
MKMark Kidd
Mark Kidd
Small intestinal neuroendocrine tumors (SI-NETs) are the most common gastrointestinal neuroendocrine tumor, but their natural history and outcome remain poorly defined, which hinders both the prediction of disease progression and appropriate therapeutic options. We examined patterns, incidence, prognosis, and outcomes of these tumors over a 30-yr period. Data were extracted from the NCI's SEER registry (1973–2002). Incidence rates, distribution, and 5-yr survival rates were analyzed and adjusted (U.S. decennial census data). Of the 18,641 NETs, 3,911 (21.0%) were SI-NETs, of which 1,953 (49.6%) were ileal. Since 1973, both SI-NET and its ileal variant have increased annually by 3.8% and 2.1%, respectively. Ileal tumors, as a percentage of SI tumors, have increased from 52% to 63.6%. The age-adjusted incidence of ileal, small intestinal, and digestive system NETs has increased 225%, 460%, and 720% over 30 yr. Ileal tumors have specifically increased in prevalence in white (274%) and black (500%) men and women (213% and 286%, respectively); an overall increase of fourfold in blacks and 2.4-fold in whites. Although 83.3% of SI-NETs were staged, 83.7% were histologically ungraded. Five-year survival rates for SI-NETs were 62.6 ± 1% (all stages), 73.8% (localized), 72% (regional), and 43.2% (distant). These have not significantly altered since 1973 (P = 0.11). SI-NETs have increased, particularly in men and in the black population, which may be due to in vivo changes, increased clinical and pathological awareness, or increased detection of tumors. SI-NETs are malignant, diagnosed late, and survival rates have remained unchanged over 30 yr.

1 August 2006 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
IMIrvin Modlin
Irvin Modlin
ILIgor Latich
Igor Latich
MZMichelle Zikusoka
Michelle Zikusoka
MKMark Kidd
Mark Kidd
GEGeeta Eick
Geeta Eick
ACAnthony K. C. Chan
Anthony K. C. Chan
Carcinoid tumors are rare, often insidious neoplasms arising from neuroendocrine cells. The majority arise in the gastrointestinal system, and are often incidentally found during investigation, although some may present as an emergency bleed or perforation. The prosaic symptoms of flushing, diarrhea, and sweating are often overlooked; thus, the diagnosis is usually much delayed and the tumor is advanced at presentation. This diagnostic delay renders effective management difficult and adversely affects outcome. This overview provides a current assessment of the evolution of the diagnostic techniques available to establish an accurate biochemical (5-hydroxyindole-3-acetic acid and chromogranin A) and topographic diagnosis (octreoscan, radio-labeled metaidobenzylguanidine, computerized tomography, magnetic resonance imaging, positron emission tomography, enteroclysis, endoscopic ultrasound, enteroscopy, capsule endoscopy, and angiography) of carcinoid tumors. The utility and shortcomings of the respective modalities available are evaluated. Although considerable advances have been made in establishing the diagnosis of carcinoid tumors and in defining the topography of metastatic disease, the major limitation is the inability to establish an early and timely diagnosis before the advent of metastatic disease.

1 March 2020 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
IMIsacco Montroni
Isacco Montroni
SRSiri Rostoft
Siri Rostoft
ASAntonino Spinelli
Antonino Spinelli
BLBarbara L. Van Leeuwen
Barbara L. Van Leeuwen
Giorgio ErcolaniGiorgio Ercolani
Giorgio Ercolani
SWSteven D. Wexner
Steven D. Wexner